Related Experiment Video
Updated: Jun 21, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Gastrointestinal stromal tumors II: medical oncology and tumor response assessment
Robert S Benjamin1, Maria Debiec-Rychter, Axel Le Cesne
1Department of Sarcoma Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Abstract:
The finding of mutations of KIT in gastrointestinal stromal tumors (GISTs) and subsequent development of kinase-directed therapy in metastatic GIST serve as a touchstone for the translation of laboratory research into clinical therapeutics. A variety of novel developments have followed the discovery of clinical activity of kinase-directed therapy against GIST. Radiological assessment of GIST challenges the standard of care for assessing tumor responses, ie, Response Evaluation Criteria in Solid Tumors (RECIST). Furthermore, the determination of the relationship of specific KIT mutations and sensitivity and resistance to kinase-directed agents and the assessment of inhibitor levels and the quality of response to those agents have implications beyond the treatment of sarcomas. These discoveries and the next chapters in this developing story are discussed in this review.
Insights
Mutations in KIT drive gastrointestinal stromal tumors (GISTs). Kinase-directed therapies show promise, but radiological assessment and understanding mutation-specific responses are key for effective GIST treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Mutations in the KIT gene are a hallmark of gastrointestinal stromal tumors (GISTs).
- The development of kinase-directed therapies has revolutionized metastatic GIST treatment.
- GIST serves as a model for translating laboratory findings into clinical applications.
Purpose of the Study:
- To review the advancements in kinase-directed therapy for GIST.
- To discuss challenges in radiological assessment of GIST response.
- To explore the relationship between KIT mutations and treatment sensitivity/resistance.
Main Methods:
- Literature review of studies on KIT mutations in GIST.
- Analysis of clinical trial data for kinase-directed therapies in GIST.
- Discussion of radiological assessment criteria and their limitations.
Main Results:
- Kinase-directed therapies have shown significant clinical activity in metastatic GIST.
- Standard radiological assessment criteria (RECIST) present challenges for GIST.
- Specific KIT mutations correlate with varying sensitivity and resistance to kinase inhibitors.
Conclusions:
- The study of KIT mutations in GIST exemplifies successful bench-to-bedside translation.
- Further research is needed to refine GIST assessment and personalize kinase inhibitor selection.
- Understanding these aspects has implications beyond sarcoma treatment.
